The Committee adopted by consensus a positive opinion for an initial marketing authorisation application for Lydaxx (tulathromycin), from Vetoquinol, a new generic product for treatment and metaphylaxis of bovine respiratory disease, treatment of infectious bovine keratoconjunctivitis, treatment and metaphylaxis of swine respiratory disease and treatment of the early stages of infectious pododermatitis.
ResearchMoz in its recently published market study offers valuable regional as well as global insights related to the “Pharma-grade Synthetic Camphor ” market. As per the study, the global “Pharma-grade Synthetic Camphor ” market is estimated to reach a value of ~US$ XX Mn/Bn in 2019 and projected to grow at a CAGR of XX% over the forecast period, 2019-2029.